Health Affairs December 11, 2024
In recent years, policymakers, regulators, and litigants have increased their focus on the practices of pharmacy benefit managers (PBMs) in response to the high cost of prescription drugs. Specifically, there has been heightened tension between the Federal Trade Commission (FTC) and the largest PBMs in the United States since 2022, when FTC launched an extensive investigation into potentially anticompetitive PBM practices.
Earlier this year, FTC released its initial findings and initiated an administrative proceeding against the three largest PBMs: Caremark, Express Scripts, and OptumRx. On November 19, 2024, those three PBMs filed a lawsuit against FTC in federal court, asking the court to prevent FTC from moving forward with the administrative proceeding. This article provides a background on the twists...
Today's Sponsors
Today's Sponsor